Ticker Details
Travere Therapeutics, Inc.
IPO Date:	August 15, 2003
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$2.72B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 2.56%
Avg Daily Range (30 D):	$0.89 | 3.12%
Avg Daily Range (90 D):	$0.80 | 2.50%

Institutional Daily Volume
Avg Daily Volume:	1.02M
Avg Daily Volume (30 D):	2.13M
Avg Daily Volume (90 D):	1.78M

Trade Size
Avg Trade Size (Sh.):	81
Avg Trade Size (Sh.) (30 D):	74
Avg Trade Size (Sh.) (90 D):	69

Institutional Trades
Total Institutional Trades:	3,796
Avg Institutional Trade:	$2.13M
Avg Institutional Trade (30 D):	$2.47M
Avg Institutional Trade (90 D):	$2.84M
Avg Institutional Trade Volume:	.11M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$3.23M
Avg Closing Trade (30 D):	$6.62M
Avg Closing Trade (90 D):	$7.25M
Avg Closing Volume:	176.51K

News

Jan 31, 2026 @ 1:50 AM TVTX ALERT: Investigation Launched into Travere Th... Source: Robbins Geller Rudman & Dowd Llp

Jan 13, 2026 @ 11:58 PM TVTX ALERT: Investigation Launched into Travere Th... Source: Robbins Geller Rudman & Dowd Llp

Dec 24, 2025 @ 11:31 PM Why Travere Therapeutics Stock Popped by Nearly 14... Source: Eric Volkman

Dec 9, 2025 @ 12:00 PM Ligand Hosts 2025 Investor Day and Introduces 2026... Source: Ligand Pharmaceuticals

Nov 21, 2025 @ 2:00 PM American Kidney Fund Hosts Third Patient Access In... Source: Lavarne A. Burton

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.29	$.03	$-.29
Diluted EPS	$-.29	$.03	$-.29
Revenue	$490.73M	$129.69M	$490.73M
Gross Profit	$480.39M	$127.14M	$480.39M
Net Income / Loss	$-25.55M	$2.73M	$-25.55M
Operating Income / Loss	$-62.82M	$-32.43M	$-62.82M
Cost of Revenue	$10.34M	$2.55M	$10.34M
Net Cash Flow	$34.5M	$-17.9M	$34.5M
PE Ratio

Splits
Nov 08, 2011	1:9